Agios Announces New Commercial Leadership Structure Read more about Agios Announces New Commercial Leadership Structure
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy Read more about Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call
Agios at Cowen 39th Annual Health Care Conference Read more about Agios at Cowen 39th Annual Health Care Conference
Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 Read more about Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019
Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients Read more about Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients
Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 Read more about Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019
Agios at Leerink Global Healthcare Conference Read more about Agios at Leerink Global Healthcare Conference
Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy Read more about Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
Agios Reports Fourth Quarter and Full Year 2018 Financial Results Read more about Agios Reports Fourth Quarter and Full Year 2018 Financial Results